February 5, 2023

Wire Service Canada

Complete Canadian News World

Anti-Covid spray vaccine, Phase 2 human trials begin in Canada

Rome, January 24 – A Canadian-made spray vaccine against Covid-19 has entered Phase 2 of human trials. The product, developed at McMaster University in Hamilton, Ontario, has already been tested in 30 volunteers with two doses of mRNA vaccine and has passed Phase 1 trials evaluating dose and safety. Pre-clinical trials show that the inhaled vaccine is more effective than the injected vaccine in stimulating an immune response by directly reaching the upper respiratory tract and lungs.

Phase 2 trials starting in the coming months will involve up to 500 participants, including those debilitated by other diseases, who have received at least three doses of the mRNA vaccine against Covid-19. 8, $2 million in new federal funding from the Canadian Institutes for Health Research.

“There is an urgent need to develop new and more effective strategies for next-generation vaccines” announced in a press release Karen MossmanVice President of Research at McMaster (In Fig) As international leaders in immunity and respiratory mucosal vaccines, our researchers moved quickly with the advent of the COVID-19 pandemic, drawing on an already existing inhaled vaccine research program focused on tuberculosis.

Fiona SmileMcMaster, a professor in the Department of Pathology and Molecular Medicine and one of the coordinators of the clinical study, which was carried out in collaboration with researchers from Dalhousie University in Nova Scotia and the University of Ottawa, says: “If we can show that the new inhaled vaccine is safe and effective, as we hope.” said the analyst “The impact on human health, medical costs and improved quality of life will be significant“.

READ  Italy approves 26% tax on crypto capital gains

The vaccine is intended to target parts of the coronavirus that don’t mutate or mutate, making it more effective against new strains. “The current Covid 19 vaccine strategy continues to chase the virus and it is clear that we cannot continue to do so” Explained Matthew MillerMcMaster is the scientific director of the Institute for Infectious Disease Research and one of the leaders of the investigation. “Our team has developed a vaccine strategy aimed at avoiding this cycle and the need to continually update these vaccines, targeting parts of the virus that are resistant to mutation and inducing stronger immunity where infection actually occurs.”

Amid epidemic fatigue and dwindling recall numbers, the researchers believe the inhaled vaccine is more convenient and attractive than vaccines that require vaccination, and predict their work could advance the use of inhaled vaccines for other respiratory infections such as tuberculosis and influenza.

Print friendly, PDF & email